We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up.
- Authors
Huynh, Kevin A.; Coopmans, Eva C.; Zamanipoor Najafabadi, Amir H.; Dirven, Linda; Peerdeman, Saskia M.; Biermasz, Nienke R.; Verstegen, Marco J. T.; van Furth, Wouter R.; the Dutch Meningioma Consortium; Boele, Florien W.; Klein, Martin; Koekkoek, Johan; Lagerwaard, Frank; van der Meer, Pim B.; Taphoorn, Martin J. B.; Moojen, Wouter A.; Reijneveld, Jaap C.
- Abstract
Purpose: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients' functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. Methods: A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients 'functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. Results: We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262–€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. Conclusion: In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients' HRQoL and needs could be beneficial in reducing disease burden and functional recovery.
- Subjects
MENINGIOMA; PATIENT reported outcome measures; ANTICONVULSANTS; GENERAL practitioners; NEUROLOGISTS; QUALITY of life
- Publication
Journal of Neuro-Oncology, 2023, Vol 161, Issue 2, p357
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-022-04223-0